What was the primary driver of the revenue decline in Q1 2009?

The primary driver of the revenue decline was an 8% decrease to $10.9 billion. This was largely due to the unfavorable impact of foreign exchange, which reduced revenues by approximately $640 million, and competitive pressures on key products such as Lipitor and the loss of exclusivity for products like Zyrtec/Zyrtec D and Camptosar.

What is the status of the Wyeth acquisition and its financial impact?

Pfizer announced a definitive agreement to acquire Wyeth for approximately $68 billion in January 2009. The transaction is expected to close in the late third or fourth quarter of 2009, subject to regulatory and shareholder approvals. The company incurred $397 million in acquisition-related costs during the quarter and raised $13.5 billion in senior unsecured notes and entered into a $22.5 billion bridge credit agreement to finance the deal, significantly increasing its long-term debt.

How is Pfizer managing its cost structure in light of revenue challenges?

Pfizer is actively implementing cost-reduction initiatives. A new initiative announced in January 2009 aims to achieve approximately $3 billion in adjusted cost reductions by the end of 2011. These initiatives involve workforce reductions, facility consolidation, and streamlining operations, which contributed to a decrease in Cost of Sales and Selling, Informational, and Administrative expenses.

What is the outlook for Pfizer's financial performance in 2009?

Pfizer forecasts 2009 revenues between $44.0 billion and $46.0 billion and Adjusted diluted EPS between $1.85 and $1.95. However, reported diluted EPS is projected to be between $1.20 and $1.35, reflecting costs associated with the pending Wyeth acquisition and other charges.

PFE 10-Q Quarterly Report Q1 FY2009 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported first-quarter 2009 results with a notable decrease in revenues, down 8% year-over-year to $10.9 billion, primarily driven by foreign exchange impacts and the continued decline of key products like Lipitor due to competitive pressures. Despite the revenue dip, income from continuing operations remained relatively stable at $2.7 billion, benefiting from cost-reduction initiatives and the absence of significant acquisition-related charges seen in the prior year. The company is actively managing its cost structure, with ongoing cost-reduction initiatives aiming for substantial savings. A significant event during the quarter was the announcement of the pending $68 billion acquisition of Wyeth, which has led to increased debt and transaction-related expenses. This strategic move is poised to reshape Pfizer's future portfolio and market position.

Financial Highlights

25 data points

Beta

Revenue

$10.87B

0.9% Gross Margin

Net Income

$2.73B

0.3% Net Margin

EPS (Diluted)

$0.40

Cash & Equivalents

$1.25B

Free Cash Flow

$2.89B

Financial Statements

Beta

Revenue	$10.87B
Cost of Revenue	$1.41B
Gross Profit	$9.46B
SG&A Expenses	$2.88B
Net Income	$2.73B
EPS (Basic)	$0.41
EPS (Diluted)	$0.40
Shares Outstanding (Basic)	6.72B
Shares Outstanding (Diluted)	6.75B

Key Highlights

1Total revenues decreased by 8% to $10.9 billion for the first quarter of 2009 compared to the prior year, largely attributed to foreign exchange headwinds and competitive pressures on key products.
2Income from continuing operations remained stable at $2.7 billion, demonstrating effective cost management despite lower revenues.
3The company announced a definitive agreement to acquire Wyeth for approximately $68 billion, a transformative deal expected to close in late 2009.
4Significant costs were incurred in relation to the pending Wyeth acquisition, including $397 million in transaction and pre-integration costs.
5Cost-reduction initiatives are progressing, with a new initiative aiming for $3 billion in adjusted cost reductions by 2011.
6Pharmaceutical segment revenues declined by 7% to $10.1 billion, impacted by patent expirations and generic competition for products like Lipitor and Chantix/Champix.
7The company's liquidity remains strong, with $34.8 billion in cash and short-term investments, although long-term debt significantly increased due to financing for the Wyeth acquisition.

PFIZER INC Quarterly Report for Q1 Ended Mar 29, 2009

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions